All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 12, 2022
Home » Blogs » BioWorld MedTech Perspectives » Telomerase; miracle medicine or just more cost?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Telomerase; miracle medicine or just more cost?

July 18, 2013
By Mark McCarty
No Comments

Little strands with big potential?
Little strands with big potential?

As is the case with many other areas of the modern world, medical science has made enormous strides over the past century or so, and it seems as though the pace of change is accelerating. It’s like being with Edwin Hubble and Georges Lemaître when they first started looking at far-flung regions of the universe. They both realized the universe was expanding, but what was not immediately obvious was that the expansion was accelerating.

To me, that’s where things stand with medical science now, and while the chatter about telomerase has been around for two decades or so, it appears the push to develop this enzyme may soon reach a critical mass. The question – assuming this idea has any legs under it at all – is whether it’ll be worth pursuing.

To quickly recap, telomerase is the agent that repairs the telomeres at the end of strands of DNA. What’s really interesting, though, is the number of disease states that seem to be associated with telomere degradation (which of course leads to degradation of DNA). The list runs from heart disease to neurodegenerative states and a range of items between, including diseases of the bone marrow.

Geron (Menlo Park, California) came up with what seems to have served as a blueprint for other efforts with a 1998 experiment with human tissues treated (apparently in vitro) with a human telomerase catalytic sub-unit, during which treated cell lines “exceeded their normal life span by 20 doublings.”

And there’s no lack of clinical interest in evaluating telomere integrity to determine whether there’s an association with disease states. For instance, clinicaltrials.gov yields 50 hits if you use telomerase as a search term.

A little skepticism is called for in this situation, however. For instance, the chatter that surrounded tissue scaffolding in times gone by now seems a bit premature. After all, patients still have to rely on ventricular assist devices and artificial pancreases, so there are fields of pursuit that just never seem to catch fire, although that’s not to say these are necessarily dead ends. Among the limitations of the telomerase concept is that the correlation between age and telomere length is not always straightforward. At the very least, this should feed a little skepticism about telomerase as a fountain-of-youth drug.

Still, the telomere/telomerase discussion is a little unique in that it offers some prospect of repairing living things at a seemingly fundamental level. The ability to administer telomerase in a targeted fashion could reverse the damage seen in heart failure if some of the current research has it right, but one has to ask whether some cancers could be treated by blocking telomerase.

But in the final crunch, even successful telomerase therapy won’t mean much if it doesn’t help us stay on the job longer. After all, we can afford only so many miracle drugs and devices before healthcare in general and Medicare in particular suck the life out of the economy, and the only way to avoid that problem is to maintain physical and mental vigor for another four or five years beyond the typical age of retirement as is now defined. We should also acknowledge that much of that problem has to do with diseases of lifestyle.

Healthcare spending would make much more sense if we could just find a way to leverage these miracle treatments into GDP growth outside the confines of the healthcare economy. The problem is that to date, all the growth in healthcare has benefited seemingly no one who’s not employed in healthcare. Can telomerase break that dynamic?

We’ll see.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 11, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 11, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing